Hunneman Completes Long-Term Lease for New Lab Research Facility in Bedford

0
678
Patrick Grady

Boston – Hunneman announced the completion of a long-term lab & office lease at 36 Crosby Drive in Bedford, MA.

The Hunneman team of Patrick Grady, Jim Boudrot and Steve James represented the tenant, PharmaEssentia, and the Landlord was Anchor Line Partners.

PharmaEssentia, headquartered in Taipei, Taiwan, leased the 11,675 SF space to serve as their new PharmaEssentia Innovation Research Center (PIRC). The new facility is expected to recruit 25 scientists and lead research in hematology, oncology, and immunology, and features a state-of-the-art lab with cutting-edge technology. Hunneman also assisted the global biopharmaceutical company with its office lease in Burlington, which stands as the firm’s U.S. HQ.

“It was a pleasure to work with the PharmaEssentia team on their latest real estate assignment, and we are very excited to see the research that emerges from PIRC,” said Hunneman’s Patrick Grady. “The PharmaEssentia team has become far more than just a client over the years, and I look forward to watching the company continue to grow at an exponential pace.”

PharmaEssentia excels as a global and rapidly-growing biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, PharmaEssentia aims to deliver effective new biologics for challenging diseases in the areas of hematology and oncology, with one approved product and a diversifying pipeline. Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, PharmaEssentia is expanding its global presence with operations in the U.S., Japan, China, and Korea, along with a world-class biologics
production facility in Taichung, Taiwan.

“The Hunneman team is an important partner for PharmaEssentia, as their knowledge of the market, experience navigating negotiations, and understanding of our needs helped us find a wonderful space for our new R&D center,” said Lih-Ling Lin, Ph.D., Chief Scientific Officer, PharmaEssentia and head of PIRC.

Advertisement